Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

被引：0
|
作者：
Axel Heidenreich
Silke Gillessen
Daniel Heinrich
Daniel Keizman
Joe M. O’Sullivan
Joan Carles
Manfred Wirth
Kurt Miller
John Reeves
Monica Seger
Sten Nilsson
Fred Saad
机构：
[1] University Hospital Cologne,Department of Urology
[2] Division of Cancer Sciences,Department of Oncology
[3] University of Manchester and the Christie,Department of Medical Oncology
[4] Medical Oncology and Haematology,Department of Urology
[5] Kantonsspital St Gallen,Department of Urology
[6] University of Bern,Department of Oncology
[7] Akershus University Hospital,Department of Urology
[8] Genitourinary Oncology Service,undefined
[9] Institute of Oncology,undefined
[10] Meir Medical Center,undefined
[11] Department of Clinical Oncology,undefined
[12] The Centre for Cancer Research and Cell Biology,undefined
[13] Queen’s University Belfast and the Northern Ireland Cancer Centre,undefined
[14] Vall d’Hebron University Hospital,undefined
[15] Vall d’Hebron Institute of Oncology,undefined
[16] University Hospital Carl-Gustav Carus,undefined
[17] Charité University Medicine Berlin,undefined
[18] Pharmaceutical Division of Bayer,undefined
[19] Karolinska University Hospital,undefined
[20] Centre Hospitalier de l’Université de Montréal (CHUM),undefined
来源：
BMC Cancer | / 19卷
关键词：
Radium-223; mCRPC, asymptomatic; Symptomatic; Bone metastases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    Wirth, Manfred
    Miller, Kurt
    Reeves, John
    Seger, Monica
    Nilsson, Sten
    Saad, Fred
    BMC CANCER, 2019, 19 (1)
  • [2] Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [3] Efficacy and tolerance of radium-223 dichloride in patients treated for castration-resistant prostate cancer with bone metastases
    Awoudou, C.
    Bathily, E. H. A. L.
    Djigo, M. S.
    Ndong, B.
    Mbodj, M.
    Paulus, P.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2024, 48 (03): : 150 - 157
  • [4] Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
    Saad, Fred
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Nilsson, Sten
    Miller, Kurt
    Wirth, Manfred
    Reeves, John
    Seger, Monica
    Carles, Joan
    Heidenreich, Axel
    CLINICAL GENITOURINARY CANCER, 2019, 17 (05) : 348 - +
  • [5] Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
    Paganelli, G.
    Procopio, G.
    Cabria, M.
    Cortesi, E.
    Tucci, M.
    Farnesi, A.
    Mango, L.
    Baldari, S.
    Hamzaj, A.
    Caffo, O.
    Marchetti, P.
    Pozza, F. Dalla
    Zucali, P.
    Barsanti, R.
    Saad, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
    Saad, F.
    Heidenreich, A.
    Heinrich, D.
    Keizman, D.
    O'Sullivan, J. M.
    Carles, J.
    Wirth, M.
    Miller, K.
    Gratt, J.
    Seger-Van Tol, M.
    Nilsson, S.
    Gillessen, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why
    Gallicchio, Rosj
    Mastrangelo, Pietro A.
    Nardelli, Anna
    Mainenti, Pier Paolo
    Colasurdo, Antonio P.
    Landriscina, Matteo
    Guglielmi, Giuseppe
    Storto, Giovanni
    TUMORI JOURNAL, 2019, 105 (05): : 367 - 377
  • [8] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
  • [9] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Hiroji Uemura
    Hirotsugu Uemura
    Nobuaki Matsubara
    Seigo Kinuya
    Makoto Hosono
    Yoko Yajima
    Toshihiko Doi
    International Journal of Clinical Oncology, 2017, 22 : 954 - 963
  • [10] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
12345